Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1995-05-22
1998-01-13
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514651, 514654, A61K 3135
Patent
active
057080356
ABSTRACT:
A method and composition are disclosed utilizing the pure R(-) isomer of fluoxetine which is a potent antidepressant and appetite suppressant substantially free of adverse effects. In addition, a method and composition are disclosed utilizing the pure R(-) isomer of fluoxetine which is useful to treat migraine headaches, pain, in particular chronic pain, psychoactive substance abuse disorders and obsessive compulsive disorders.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3630200 (1971-12-01), Higuchi
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4018895 (1977-04-01), Molloy et al.
patent: 4194009 (1980-03-01), Molloy et al.
patent: 4313896 (1982-02-01), Molloy et al.
patent: 4314081 (1982-02-01), Molloy et al.
patent: 4329356 (1982-05-01), Holland
patent: 4444778 (1984-04-01), Coughlin
patent: 4590213 (1986-05-01), Stark
patent: 4594358 (1986-06-01), Hynes
patent: 4596807 (1986-06-01), Crosby
patent: 4626549 (1986-12-01), Molloy et al.
patent: 4647591 (1987-03-01), Cherkin et al.
patent: 4698342 (1987-10-01), Crosby
patent: 4777173 (1988-10-01), Shrotyia et al.
patent: 4797286 (1989-01-01), Thakkar et al.
patent: 4847092 (1989-07-01), Thakkar et al.
patent: 4868344 (1989-09-01), Brown
patent: 4895845 (1990-01-01), Seed
patent: 4918207 (1990-04-01), Brown
patent: 4918242 (1990-04-01), Brown
patent: 4918246 (1990-04-01), Brown
patent: 4971998 (1990-11-01), Wurtman et al.
patent: 5356934 (1994-10-01), Robertson et al.
Power-Smith, "Beneficial Sexual Side-effects from Fluoxetine," Brit. J. Psychiatry 164:249-250 (1994).
Saper et al., "Double-Blind Trial of Fluoxetine: Chronic Daily Headache and Migraine," Headache 34:497-502 (1994).
Stevens et al., "Interaction of the Enantiomers of Fluoxetine and Norfluoxetine with Human Liver Cytochromes P450," J. Pharmacology & Experimental Therapeutics 226(7):964-971 (1993).
Bergstrom et al., "Quantification and Mechanism of the Fluoxetine and Tricyclic Antidepressant Interaction," Clin. Pharmacol. Ther. 51:239-248 (1992).
Adly et al., "Fluoxetine Prophylaxis of Migraine," Headache 32:101-104 (1992).
Caccia et al., "Influence of Dose and Route of Administration on the Kinetics of Fluoxetine and Its Metabolite Norfluoxetine in the Rat", Psychopharmacology 100:509-514 (1990).
Physicians Desk Reference, pp. 905-908, 44th Ed., Medical Economics Data Production Co., N.J. (1990).
Teicher et al., "Emergence of Intense Suicidal Preoccupation During Fluoxetine Treatment", Am. J. Psychiatry 147(2):207-210 (1990).
Wong et al., "Fluoxetine and Its Two Enantiomers as Selective Serotonin Uptake Inhibitors", Acta Pharm. Nord. 2(3):171-180 (1990).
Corey and Reichard, "Enantioselective and Practical Synthesis of R-and S-Fluoxetines", Tetrahedron Lett. 30(39):5207-5210 (1989).
Coutts and Baker, "Implications of Chirality and Geometric Isomerism in Some Psychoactive Drugs and Their Metabolites", Chirality 1:99-120 (1989).
Coutts and Baker, "Metabolic Implications of Chiral Centres in Psychotropic Drugs", Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 13:405-417 (1989).
Jamali et al., "Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls", J. Pharm. Sci. 78(9):695-715 (1989).
Gao and Sharpless, "Asymmetric Synthesis of Both Enantiomers of Tomoxetine and Fluoxetine. Selective Reduction of 2,3-Epoxycinnamyl Alcohol with Red-Al", J. Org. Chem. 53(17):4081-4084 (1988).
Kim and Wurtman, "Selective Effects of CGS 10686B, d1-Fenfluramine or Fluoxetine on Nutrient Selection", Physiology & Behavior 42:319-322 (1988).
Robertson et al., "Absolute Configurations and Pharmacological Activities of the Optical Isomers of Fluoxetine, a Selective Serotonin-Uptake Inhibitor", J. Med. Chem. 31:1412-1417 (1988).
Wong et al., "Suppression of Food Intake in Rats by Fluoxetine: Comparison of Enantiomers and Effects of Serotonin Antagonists", Pharmacology Biochemistry & Behavior 31:475-479 (1988).
Benfield et al., "Fluoxetine: A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Depressive Illness", Drugs 32:481-508 (1986).
Fuller and Snoddy, "Fluoxetine Enantiomers as Antagonists of p-Chloroamphetamine Effects in Rats", Pharmacology Biochemistry & Behavior 24:281-284 (1986).
Scrips' New Product Review, No. 7, pp. 13-14 (1986).
Wong et al., "Inhibition of Serotonin Uptake by Optical Isomers of Fluoxetine", Drug Development Research 6:397-403 (1985).
Bremner, "Fluoxetine in Depressed Patients: A Comparison with Imipramine", J. Clin. Psychiatry 45(10):414-420 (1984).
Barberich Timothy J.
Teicher Martin H.
Young James W.
Criares Theodore J.
McLean Hospital
Sepracor Inc.
LandOfFree
Methods of use and compositions of R(-) fluoxetine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of use and compositions of R(-) fluoxetine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of use and compositions of R(-) fluoxetine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-326811